183 related articles for article (PubMed ID: 31665029)
1. The clinical characteristics and molecular mechanism of pituitary adenoma associated with meningioma.
Zhu H; Miao Y; Shen Y; Guo J; Xie W; Zhao S; Dong W; Zhang Y; Li C
J Transl Med; 2019 Oct; 17(1):354. PubMed ID: 31665029
[TBL] [Abstract][Full Text] [Related]
2. Germline mutations in
Zhu H; Miao Y; Shen Y; Guo J; Xie W; Zhao S; Dong W; Zhang Y; Li C
Oncol Lett; 2020 Jul; 20(1):561-568. PubMed ID: 32565981
[TBL] [Abstract][Full Text] [Related]
3. The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas.
Monsalves E; Juraschka K; Tateno T; Agnihotri S; Asa SL; Ezzat S; Zadeh G
Endocr Relat Cancer; 2014 Aug; 21(4):R331-44. PubMed ID: 25052915
[TBL] [Abstract][Full Text] [Related]
4. Cucurbitacin I blocks cerebrospinal fluid and platelet derived growth factor-BB stimulation of leptomeningeal and meningioma DNA synthesis.
Johnson MD; O'Connell MJ; Walter K
BMC Complement Altern Med; 2013 Nov; 13():303. PubMed ID: 24188277
[TBL] [Abstract][Full Text] [Related]
5. mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.
Beauchamp RL; Erdin S; Witt L; Jordan JT; Plotkin SR; Gusella JF; Ramesh V
J Biol Chem; 2021; 296():100157. PubMed ID: 33273014
[TBL] [Abstract][Full Text] [Related]
6. Osteoglycin promotes meningioma development through downregulation of NF2 and activation of mTOR signaling.
Mei Y; Du Z; Hu C; Greenwald NF; Abedalthagafi M; Agar NYR; Dunn GP; Bi WL; Santagata S; Dunn IF
Cell Commun Signal; 2017 Sep; 15(1):34. PubMed ID: 28923059
[TBL] [Abstract][Full Text] [Related]
7. Nelfinavir induces radiation sensitization in pituitary adenoma cells.
Zeng J; See AP; Aziz K; Thiyagarajan S; Salih T; Gajula RP; Armour M; Phallen J; Terezakis S; Kleinberg L; Redmond K; Hales RK; Salvatori R; Quinones-Hinojosa A; Tran PT; Lim M
Cancer Biol Ther; 2011 Oct; 12(7):657-63. PubMed ID: 21811091
[TBL] [Abstract][Full Text] [Related]
8. Lopinavir inhibits meningioma cell proliferation by Akt independent mechanism.
Johnson MD; O'Connell M; Pilcher W
J Neurooncol; 2011 Feb; 101(3):441-8. PubMed ID: 20596751
[TBL] [Abstract][Full Text] [Related]
9. Histochemical and immunohistochemical features of a case showing association of meningioma and prolactinoma containing amyloid.
Canda T; Sengiz S; Canda MS; Acar UD; Erbayraktar RS; Yilmaz HS
Brain Tumor Pathol; 2002; 19(1):1-3. PubMed ID: 12455881
[TBL] [Abstract][Full Text] [Related]
10. Mutations of the MEN1 tumor suppressor gene in sporadic pituitary tumors.
Wenbin C; Asai A; Teramoto A; Sanno N; Kirino T
Cancer Lett; 1999 Jul; 142(1):43-7. PubMed ID: 10424779
[TBL] [Abstract][Full Text] [Related]
11. Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
Yesilöz Ü; Kirches E; Hartmann C; Scholz J; Kropf S; Sahm F; Nakamura M; Mawrin C
Neuro Oncol; 2017 Aug; 19(8):1088-1096. PubMed ID: 28482067
[TBL] [Abstract][Full Text] [Related]
12. Celastrol Induces Apoptosis and Autophagy via the AKT/mTOR Signaling Pathway in the Pituitary ACTH-secreting Adenoma Cells.
Cai Z; Qian B; Pang J; Tan ZB; Zhao K; Lei T
Curr Med Sci; 2022 Apr; 42(2):387-396. PubMed ID: 35419676
[TBL] [Abstract][Full Text] [Related]
13. Increased menin expression in sporadic pituitary adenomas.
Wrocklage C; Gold H; Hackl W; Buchfelder M; Fahlbusch R; Paulus W
Clin Endocrinol (Oxf); 2002 May; 56(5):589-94. PubMed ID: 12030908
[TBL] [Abstract][Full Text] [Related]
14. mTOR Signaling and Potential Therapeutic Targeting in Meningioma.
Pinker B; Barciszewska AM
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216092
[TBL] [Abstract][Full Text] [Related]
15. MEN1 and pituitary adenomas.
Delemer B
Ann Endocrinol (Paris); 2012 Apr; 73(2):59-61. PubMed ID: 22542456
[TBL] [Abstract][Full Text] [Related]
16. mTORC1 inhibitors suppress meningioma growth in mouse models.
Pachow D; Andrae N; Kliese N; Angenstein F; Stork O; Wilisch-Neumann A; Kirches E; Mawrin C
Clin Cancer Res; 2013 Mar; 19(5):1180-9. PubMed ID: 23406776
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
Dai C; Zhang B; Liu X; Ma S; Yang Y; Yao Y; Feng M; Bao X; Li G; Wang J; Guo K; Ma W; Xing B; Lian W; Xiao J; Cai F; Zhang H; Wang R
Endocrinology; 2013 Mar; 154(3):1247-59. PubMed ID: 23384836
[TBL] [Abstract][Full Text] [Related]
18. Effect of lncRNA HULC knockdown on rat secreting pituitary adenoma GH3 cells.
Rui QH; Ma JB; Liao YF; Dai JH; Cai ZY
Braz J Med Biol Res; 2019; 52(4):e7728. PubMed ID: 30994730
[TBL] [Abstract][Full Text] [Related]
19. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients.
Trouillas J; Labat-Moleur F; Sturm N; Kujas M; Heymann MF; Figarella-Branger D; Patey M; Mazucca M; Decullier E; Vergès B; Chabre O; Calender A;
Am J Surg Pathol; 2008 Apr; 32(4):534-43. PubMed ID: 18300794
[TBL] [Abstract][Full Text] [Related]
20. MEN1 gene replacement therapy reduces proliferation rates in a mouse model of pituitary adenomas.
Walls GV; Lemos MC; Javid M; Bazan-Peregrino M; Jeyabalan J; Reed AA; Harding B; Tyler DJ; Stuckey DJ; Piret S; Christie PT; Ansorge O; Clarke K; Seymour L; Thakker RV
Cancer Res; 2012 Oct; 72(19):5060-8. PubMed ID: 22915754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
